Country for PR: Hong Kong
Contributor: PR Newswire Asia (Hong Kong)
Friday, April 26 2019 - 12:00
AsiaNet
BD Launches Preventing Risks of Infections and Medication Errors in IV Therapy (PRIME) in Asia
SINGAPORE, April 26, 2019 /PRNewswire-AsiaNet/ --

BD (Becton, Dickinson and Company), a leading global medical technology 
company, has launched a new patient safety program for hospitals, called 
Preventing Risks of Infections and Medication Errors in IV Therapy (PRIME). 
Aimed at addressing the top two challenges in a hospital setting - infection 
prevention and medication safety - PRIME is developed by Joint Commission 
International for Patient Safety, with sponsorship by BD. 

Photo - https://photos.prnasia.com/prnh/20190425/2446684-1 
Logo - https://photos.prnasia.com/prnh/20190425/2446684-1LOGO 

Speaking about JCI's initiation of PRIME with BD, Dr. Marwa J. Zohdy, vice 
president, Global Consulting Services, Joint Commission Resources/Joint 
Commission International (JCI) said, "The preparation and administration of 
medication is critical to safe, high-quality patient care around the world. At 
JCI, we recognize a fundamental need for evidence-based capability building on 
this topic, and the unique PRIME program addresses that need. Leading experts 
from JCI with the support of BD have created a practical curriculum that will 
bring critical skills to life."

A unique programmatic approach towards patient safety will be implemented over 
a six-month duration, composed of goal-setting, constant progress review, 
tele-consultations with experts and scientific updates through webinars. 
Hospitals will be certified upon successful completion of the program. 

Raymond Chow, vice president for Central Asia at BD said, "Administration of 
medication via invasive routes presents unique risks. Particularly in emerging 
countries, the risks may be greater due to lack of awareness, standards, 
assessment of skills and adoption of safe technology and practices. PRIME is 
set to address these very risks that are often unnoticed due to inadequate 
focus or knowledge of streamlined processes in medication management." 

PRIME was officially launched between 22-26 April in the following countries: 
South Korea, Japan, Malaysia, Thailand, Indonesia, Philippines, Vietnam and 
India. To date, 21 leading hospitals have signed up for the program. 

About BD

BD is one of the largest global medical technology companies in the world and 
is advancing the world of health by improving medical discovery, diagnostics 
and the delivery of care. The company supports the heroes on the frontlines of 
health care by developing innovative technology, services and solutions that 
help advance both clinical therapy for patients and clinical process for health 
care providers. BD and its 65,000 employees have a passion and commitment to 
help enhance the safety and efficiency of clinicians' care delivery process, 
enable laboratory scientists to accurately detect disease and advance 
researchers' capabilities to develop the next generation of diagnostics and 
therapeutics. BD has a presence in virtually every country and partners with 
organizations around the world to address some of the most challenging global 
health issues. By working in close collaboration with customers, BD can help 
enhance outcomes, lower costs, increase efficiencies, improve safety and expand 
access to health care. For more information on BD, please visit bd.com. 

SOURCE  BD
Translations

Vietnamese